MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
www.pressreleasecc.com
June 18, 2026 at 6:12 AM
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Monday, February 16, 2026
By: Salong Debbarma on Monday, February 16, 2026
MEDIPOST files IND amendment to FDA for Phase III osteoarthritis trial
MEDIPOST has submitted an IND amendment to the US FDA to initiate a Phase III trial of its cell therapy for knee osteoarthritis.
www.clinicaltrialsarena.com
February 17, 2026 at 12:36 AM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Monday, February 16, 2026
By: Salong Debbarma on Monday, February 16, 2026
Feed: "Endpoints News"
By: Kyle LaHucik on Friday, January 9, 2026
By: Kyle LaHucik on Friday, January 9, 2026
Medipost gets $140M to take Korean stem cell therapy into US
A Seoul-area biotech has raised $140 million to bring its allogeneic cell therapy, approved in South Korea since 2012, into the US and Japan.
endpoints.news
January 9, 2026 at 7:46 PM
Feed: "Endpoints News"
By: Kyle LaHucik on Friday, January 9, 2026
By: Kyle LaHucik on Friday, January 9, 2026
Alaskans own 4,451 shares of Medipost Co Ltd worth $34,830. It's in the 🏥, Health Care Equipment & Services industry, based in 🇰🇷 South Korea.
April 7, 2025 at 9:25 AM
Alaskans own 4,451 shares of Medipost Co Ltd worth $34,830. It's in the 🏥, Health Care Equipment & Services industry, based in 🇰🇷 South Korea.
Indonesian benchmark index drops 4.95 percent to 5,647.084, the lowest level since December 2020. Medipost achieves FDA alignment on a Phase 3 study design for its CARTISTEM BLA submission. Taiwan opposition leader promotes cross-strait peace during a visit to the United States.
June 4, 2026 at 3:43 AM
Indonesian benchmark index drops 4.95 percent to 5,647.084, the lowest level since December 2020. Medipost achieves FDA alignment on a Phase 3 study design for its CARTISTEM BLA submission. Taiwan opposition leader promotes cross-strait peace during a visit to the United States.
Funding Raises: #Parloa $350M Series D; #Rain $250M Series C; #OrcaBio $250M Series F; #AirNexisTherapeutics $200M Series A; #HarmattanAI $200M Series B; #JetZero $175M Series B; #Medipost $140M; #Torq $140M; #DefenseUnicorns $136M Series B; #Deepgram $130M Series C
January 16, 2026 at 11:30 PM
Funding Raises: #Parloa $350M Series D; #Rain $250M Series C; #OrcaBio $250M Series F; #AirNexisTherapeutics $200M Series A; #HarmattanAI $200M Series B; #JetZero $175M Series B; #Medipost $140M; #Torq $140M; #DefenseUnicorns $136M Series B; #Deepgram $130M Series C
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026…
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026…
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative dise...
news-area.com
July 8, 2026 at 3:30 PM
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026…
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026…
Medipost secures $8 million upfront in Japan licensing deal for knee therapy todayheadline
Medipost secures $8 million upfront in Japan licensing deal for knee therapy
Medipost secures $8 million upfront in Japan licensing deal for knee therapy
Medipost secures $8 million upfront in Japan licensing deal for knee therapy todayheadline
Medipost secures $8 million upfront in Japan licensing deal for knee therapy
todayheadline.co
December 19, 2025 at 5:22 AM
Medipost secures $8 million upfront in Japan licensing deal for knee therapy todayheadline
Medipost secures $8 million upfront in Japan licensing deal for knee therapy
Medipost secures $8 million upfront in Japan licensing deal for knee therapy
MEDIPOST Gains FDA Approval for Critical CARTISTEM Clinical Study in the U.S.#South_Korea#Seoul#FDA_Approval#CARTISTEM#MEDIPOST
MEDIPOST Gains FDA Approval for Critical CARTISTEM Clinical Study in the U.S.
MEDIPOST has secured FDA agreement for a pivotal Phase 3 study of CARTISTEM in the U.S., streamlining its path to market. This milestone also enhances financial efficiency.
third-news.com
June 4, 2026 at 3:46 AM
MEDIPOST Gains FDA Approval for Critical CARTISTEM Clinical Study in the U.S.#South_Korea#Seoul#FDA_Approval#CARTISTEM#MEDIPOST
CARTISTEM® Achieves Significant Efficacy Milestones in Japan's Phase 3 Clinical Trials#Japan#Tokyo#Osteoarthritis#CARTISTEM#MEDIPOST
CARTISTEM® Achieves Significant Efficacy Milestones in Japan's Phase 3 Clinical Trials
MEDIPOST's CARTISTEM® has met key efficacy endpoints in Japan's Phase 3 trials, showcasing remarkable improvements in osteoarthritis treatment, setting a solid foundation for its global commercialization.
third-news.com
May 14, 2026 at 12:15 PM
CARTISTEM® Achieves Significant Efficacy Milestones in Japan's Phase 3 Clinical Trials#Japan#Tokyo#Osteoarthritis#CARTISTEM#MEDIPOST
MEDIPOST Partners with Teikoku Seiyaku for Revolutionary Osteoarthritis Treatment in Japan#South_Korea#Seoul#CARTISTEM#MEDIPOST#Teikoku_Seiyaku
MEDIPOST Partners with Teikoku Seiyaku for Revolutionary Osteoarthritis Treatment in Japan
MEDIPOST has announced a strategic partnership with Teikoku Seiyaku to bring CARTISTEM®, a groundbreaking treatment for knee osteoarthritis, to Japan. This collaboration is set to enhance the availability of innovative therapies for patients in need.
third-news.com
December 19, 2025 at 5:10 AM
MEDIPOST Partners with Teikoku Seiyaku for Revolutionary Osteoarthritis Treatment in Japan#South_Korea#Seoul#CARTISTEM#MEDIPOST#Teikoku_Seiyaku
🌟 そして、ヒカルさんが離婚を発表し、ともに結婚指輪を外すシーンが注目されました。ファンからは様々なコメントが寄せられています。 💔
🎉 その他、帝國製薬が韓国MEDIPOST社の変形性膝関節症に対する再生医療等製品の国内販売権を取得しました。また、高市内閣の支持率が73%で最高を更新しました。 🌈
🌸 雰囲気や感情：明るくてポジティブなニュースが多いですね！ 🌞 しかし、時には深刻な話題もありますが、全体的に前向きな雰囲気です。 🌈
# 最新ニュース # ニュースまとめ # ポジティブニュース
🎉 その他、帝國製薬が韓国MEDIPOST社の変形性膝関節症に対する再生医療等製品の国内販売権を取得しました。また、高市内閣の支持率が73%で最高を更新しました。 🌈
🌸 雰囲気や感情：明るくてポジティブなニュースが多いですね！ 🌞 しかし、時には深刻な話題もありますが、全体的に前向きな雰囲気です。 🌈
# 最新ニュース # ニュースまとめ # ポジティブニュース
December 21, 2025 at 8:00 PM
🌟 そして、ヒカルさんが離婚を発表し、ともに結婚指輪を外すシーンが注目されました。ファンからは様々なコメントが寄せられています。 💔
🎉 その他、帝國製薬が韓国MEDIPOST社の変形性膝関節症に対する再生医療等製品の国内販売権を取得しました。また、高市内閣の支持率が73%で最高を更新しました。 🌈
🌸 雰囲気や感情：明るくてポジティブなニュースが多いですね！ 🌞 しかし、時には深刻な話題もありますが、全体的に前向きな雰囲気です。 🌈
# 最新ニュース # ニュースまとめ # ポジティブニュース
🎉 その他、帝國製薬が韓国MEDIPOST社の変形性膝関節症に対する再生医療等製品の国内販売権を取得しました。また、高市内閣の支持率が73%で最高を更新しました。 🌈
🌸 雰囲気や感情：明るくてポジティブなニュースが多いですね！ 🌞 しかし、時には深刻な話題もありますが、全体的に前向きな雰囲気です。 🌈
# 最新ニュース # ニュースまとめ # ポジティブニュース
#CRL Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
https://www.stocktitan.net/news/CRL/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-hh8ncl11xott.html
https://www.stocktitan.net/news/CRL/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-hh8ncl11xott.html
New Charles River–MEDIPOST deal targets safer cell therapies worldwide
Non-exclusive MOU expands GMP testing support for MEDIPOST’s APAC and North America cell therapy pipeline, after treating 36,000 patients in South Korea.
www.stocktitan.net
May 13, 2026 at 12:00 PM
#CRL Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
https://www.stocktitan.net/news/CRL/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-hh8ncl11xott.html
https://www.stocktitan.net/news/CRL/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-hh8ncl11xott.html
MEDIPOST enters multi-year exclusive licensing deal with Teikoku Seiyaku for CARTISTEM® commercialization in Japan #RegenerativeMedicine #HealthcareInnovation #JapanHealthcare #Partnership #CARTISTEM
MEDIPOST enters multi-year exclusive licensing deal with Teikoku Seiyaku for CARTISTEM® commercialization in Japan
SEOUL — MEDIPOST Co., Ltd., a leading South Korean regenerative medicine company, has announced a strategic multi-year licensing partnership with Japan-based Teikoku Seiyaku Co., Ltd., granting exclusive commercialization rights for its cartilage repair therapy CARTISTEM® in Japan. The agreement strengthens MEDIPOST’s footprint in one of the world’s most advanced medical markets while addressing Japan’s significant […]
dlvr.it
December 21, 2025 at 6:10 PM
MEDIPOST enters multi-year exclusive licensing deal with Teikoku Seiyaku for CARTISTEM® commercialization in Japan #RegenerativeMedicine #HealthcareInnovation #JapanHealthcare #Partnership #CARTISTEM
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis - bioinformant.com/medipost-inc...
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis | BioInformant
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-...
bioinformant.com
July 15, 2026 at 4:26 PM
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis - bioinformant.com/medipost-inc...
Thoughts on this? >> Press Release Service: Advanced Therapy Medicinal Products
Global Strategic Business Report 2025, with Profiles of Bluebird
Bio, Gilead Sciences,… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharmaceutical #pharma #healthcare
Global Strategic Business Report 2025, with Profiles of Bluebird
Bio, Gilead Sciences,… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharmaceutical #pharma #healthcare
Press Release Service: Advanced Therapy Medicinal Products
Global Strategic Business Report 2025, with Profiles of Bluebird
Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene,
MediPost, Organogenesis and more - ResearchAndMarkets.com - CRISPR
Medicine News
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and more - ResearchAndMarkets.com CRISPR Medicine News
dlvr.it
April 22, 2025 at 5:30 AM
Thoughts on this? >> Press Release Service: Advanced Therapy Medicinal Products
Global Strategic Business Report 2025, with Profiles of Bluebird
Bio, Gilead Sciences,… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharmaceutical #pharma #healthcare
Global Strategic Business Report 2025, with Profiles of Bluebird
Bio, Gilead Sciences,… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharmaceutical #pharma #healthcare
Thoughts on this? >> MEDIPOST, Inc. Expands U.S. Presence with Key Executive
Appointments, advances toward Phase III clinical trial of
CARTISTEM® in North America -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #healthcare #pharma #biotech
Appointments, advances toward Phase III clinical trial of
CARTISTEM® in North America -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #healthcare #pharma #biotech
MEDIPOST, Inc. Expands U.S. Presence with Key Executive
Appointments, advances toward Phase III clinical trial of
CARTISTEM® in North America - BioSpace
MEDIPOST, Inc. Expands U.S. Presence with Key Executive Appointments, advances toward Phase III clinical trial of CARTISTEM® in North America BioSpace
dlvr.it
December 4, 2024 at 6:01 AM
Thoughts on this? >> MEDIPOST, Inc. Expands U.S. Presence with Key Executive
Appointments, advances toward Phase III clinical trial of
CARTISTEM® in North America -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #healthcare #pharma #biotech
Appointments, advances toward Phase III clinical trial of
CARTISTEM® in North America -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #healthcare #pharma #biotech
Medipost obtains FDA alignment on a Phase 3 pivotal study design as part of its U.S. BLA submission strategy for CARTISTEM®.
June 4, 2026 at 3:39 AM
Medipost obtains FDA alignment on a Phase 3 pivotal study design as part of its U.S. BLA submission strategy for CARTISTEM®.
Biopharma bites: Novartis' Florida facility, plus fresh funds for Orca, MEDIPOST, a16z $NVS firstwordpharma.com/story/7052599
January 10, 2026 at 4:15 AM
Biopharma bites: Novartis' Florida facility, plus fresh funds for Orca, MEDIPOST, a16z $NVS firstwordpharma.com/story/7052599